Condition (MeSH)
Premenstrual Dysphoric Disorder
ClinicalTrials.gov lists 42 trials for Premenstrual Dysphoric Disorder or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
42 of the 42 trials are tagged with Premenstrual Dysphoric Disorder itself; the rest are tagged with a narrower condition beneath it.
When did Premenstrual Dysphoric Disorder trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 4 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 2 |
| 2019 | 2 |
| 2018 | 2 |
| 2016 | 1 |
| 2015 | 3 |
| 2013 | 4 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Premenstrual Dysphoric Disorder trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 3 |
| Phase 2/3 | 2 |
| Phase 3 | 3 |
| Phase 4 | 7 |
| Not applicable | 17 |
| Observational | 8 |
How many Premenstrual Dysphoric Disorder trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 8 |
| Active, not recruiting | 1 |
| Completed | 23 |
| Terminated | 2 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Premenstrual Dysphoric Disorder trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bayer | 2 |
| Tel-Aviv Sourasky Medical Center | 2 |
| Asarina Pharma | 1 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| EE20/DRSP (BAY86-5300) | 2 |
| Paroxetine IR | 2 |
| Sertralin | 2 |
| Ulipristal Acetate - open label | 1 |
| IM Oxytocin | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Premenstrual Dysphoric Disorder? (33)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Cortisol and ACTH response to Dex/CRH testing and 24-hour urine free cortisol levels in women with and without premenstrual dysphoric disorder. | Psychoneuroendocrinology | 2025 | Yes |
| Emotion regulation-based internet-delivered cognitive behavioural therapy for premenstrual dysphoric disorder: study protocol for a randomised controlled trial in Sweden. | BMJ open | 2025 | Yes |
| GABAergic neuroactive steroid response to sertraline in premenstrual dysphoric disorder. | Psychoneuroendocrinology | 2024 | Yes |
| Neuroactive steroid hormone trajectories across the menstrual cycle in premenstrual dysphoric disorder (PMDD): the PHASE study. | Molecular psychiatry | 2024 | Yes |
| Luteal phase sertraline treatment of premenstrual dysphoric disorder (PMDD): Effects on markers of hypothalamic pituitary adrenal (HPA) axis activation and inflammation. | Psychoneuroendocrinology | 2024 | Yes |
Showing 5 of 33 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.